Bavarian Nordic monkeypox vaccine wins EU approval | Inquirer News

Bavarian Nordic monkeypox vaccine wins EU approval

/ 03:17 PM July 25, 2022

Bavarian Nordic monkeypox vaccine wins EU approval

 An employee of the vaccine company Bavarian Nordic shows a picture of a vaccine virus on a display in a laboratory of the company in Martinsried near Munich, Germany, May 24, 2022. The company, headquartered in Denmark, is the only one in the world to have approval for a smallpox vaccine called Jynneos in the U.S. and Imvanex in Europe, which is also effective against monkeypox. REUTERS FILE PHOTO

OSLO — Danish biotechnology company Bavarian Nordic said on Monday the European Commission had given permission for its Imvanex vaccine to be marketed as protection against monkeypox, as recommended last week by the European Medicines Agency (EMA).

The approval comes just one day after the World Health Organization issued a high-level alert declaring the rapidly spreading monkeypox outbreak as a global health emergency.

Article continues after this advertisement

“The availability of an approved vaccine can significantly improve nations’ readiness to fight emerging diseases, but only through investments and structured planning of the biological preparedness,” Bavarian Chief Executive Paul Chaplin said.

FEATURED STORIES

Bavarian’s vaccine, the only one to have won approval for the prevention of monkeypox disease in the United States and Canada, has in the EU so far only been approved to treat smallpox.

But the company has supplied the vaccine to several EU countries during the current monkeypox outbreak for what is known as “off-label” use.

Article continues after this advertisement

The approval is valid in all European Union Member States as well as in Iceland, Liechtenstein, and Norway, Bavarian Nordic said in a statement.

Article continues after this advertisement

The development of Imvanex was made possible through significant investments from the U.S. government during the past two decades, the company added.

Article continues after this advertisement

Bavarian’s share price has risen by 122% in the last three months, driven by strong demand for the monkeypox vaccine.

RELATED STORIES

Article continues after this advertisement

US adds 2.5M Bavarian Nordic monkeypox vaccine doses, expects more in July

Monkeypox outbreak constitutes global health emergency – WHO

PH still monkeypox-free amid WHO global alert

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

EU secures 54,000 more doses of Bavarian Nordic’s monkeypox vaccine

TAGS: monkeypox, Vaccines

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.